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Abstract We have previously observed that treatment of rat 
islets of Langerhans with interleukin-1 p for 12 h results in nitric 
oxide-dependent inhibition of insulin secretion, while 48 h 
treatment increased rates of islet cell death by apoptosis. Here, 
we demonstrate that interleukin-1 P-mediated nitric oxide for-
mation and inhibition of insulin secretion are significantly 
reduced by 24 h pretreatment of rat islets of Langerhans with 
insulin-like growth factor I (IGF-I). IGF-I decreased cytokine 
induction of nitric oxide synthase in islets. Use of an arginine 
analogue in culture or IGF-I pretreatment of islets were also 
effective in protecting islets against cytokine-mediated apoptotic 
cell death. We conclude that IGF-I antagonises inhibitory and 
cytotoxic effects of cytokines in rat islets. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Insulin-like growth factor I (IGF-I) is a single chain poly-
peptide of 7-8 kDa [1] which has insulin-like effects on glu-
cose transport and blood glucose levels [1]. Receptors for 
IGF-I have been observed on rat islet (3-cells and oc-cells [2]. 
Short-term treatment of either perfused isolated islets [3] or 
whole pancreas [4] with IGF-I inhibited insulin secretion but 
had no effect on glucagon secretion [4]. Recombinant human 
IGF-I has been shown to reduce but not eliminate insulitis 
and to delay the onset of diabetes, induced by adoptive T-cell 
transfer, in NOD mice [5]. The authors speculated that IGF-I 
may directly promote P-cell regeneration, protect against cy-
tokine attack or reduce nitric oxide formation [5]. 
Interleukin-1 P (IL-ip) induces expression of the calcium-
independent isoform form of the enzyme nitric oxide synthase 
(type II) and increases nitric oxide formation in rat islets of 
Langerhans [6-8]. IL-1 p-mediated nitric oxide affects a num-
ber of islet parameters: it inhibits insulin secretion [9,10], glu-
cose oxidation [10], the mitochondrial enzyme aconitase [10], 
cAMP formation [11] and lowers NAD levels [12]. IL-ip also 
stimulates islet cGMP formation [11,13] and has islet DNA-
damaging effects [14]. IL-ip causes islet cell death by apopto-
sis [15,16], an effect reversed by an inhibitor of nitric oxide 
synthase [15]. Increases in cellular cGMP levels and protein 
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kinase G activity have been implicated in nitric oxide-medi-
ated apoptosis signalling in insulin-containing cells [17]. Com-
binations of IL-ip, interferon-y, and/or tumour necrosis fac-
tor-a are more potent at inhibiting insulin secretion [9,18], 
lowering cell viability [16,19] and inducing nitric oxide syn-
thase than single cytokines. 
Induction of nitric oxide synthase by interleukin-1 p or tu-
mour necrosis factor a in rat vascular smooth muscle cells is 
inhibited by IGF-I [20]. IGF-I has also been shown to be an 
effective anti-apoptotic agent [21]. Reversal of cytokine-in-
duced impairment of rat islets by anti-inflammatory cytokines 
has been difficult to demonstrate. The aim of this study was 
therefore to explore whether IGF-I protected against cyto-
kine-mediated inhibition of insulin secretion, stimulation of 
nitric oxide formation and cell death by apoptosis in rat islets 
of Langerhans. 
2. Materials and methods 
Reagents were obtained from the following sources: tissue culture 
RPMI 1640 and foetal calf serum were from Gibco BRL (Paisley, 
UK); rat interferon-y, specific activity >7.5Xl06 U/mg (Genzyme, 
UK); JV -^monomethyl arginine (NMMA) (Calbiochem, Nottingham, 
UK); anti-iNOS (murine macrophage, inducible) rabbit polyclonal 
antibody (Affiniti Research Products Ltd, UK); acrylamide, arginine 
hydrochloride, bis-acrylamide, collagenase type XI, leupeptin, pepsta-
tin, phenylmethylsulphonyl fluoride, acridine orange, sodium dodecyl 
sulphate (SDS), horseradish peroxidase-conjugated goat anti-mouse 
IgG affinity isolated antibody and dithiothreitol (Sigma Chemicals 
Poole, UK); L-[U-HC]arginine monohydrochloride (318 mCi/mmol) 
and enhanced chemiluminescence kit (Amersham, Bucks., UK); 
Poly-Prep chromatography columns, electrophoresis equipment and 
Dowex AG50W-x8 cation exchange resin (Bio-Rad Laboratories, 
Richmond, CA, USA); Immobilon-P PVDF filters (Millipore, UK); 
interleukin-1 P (86/558), tumour necrosis factor-a (88/784) and insulin-
like growth factor I (87/518) were from Dr Dennis Schulster at the 
National Institute of Biological Standards and Controls, UK via a 
BBSRC CASE-studentship agreement. 
2.1. Islet isolation, culture and cytokine treatment 
Islets of Langerhans were isolated under aseptic conditions from 
collagenase-digested pancreata of adult female (180-250 g) or un-
weaned Sprague-Dawley rats [11,18]. Batches of 100^400 islets were 
cultured in RPMI 1640 medium containing 5.5 mM glucose, penicillin 
(50 U/ml), streptomycin (50 |ig/ml) and 5% foetal calf serum for 24 h 
before experimental treatments. Cytokine treatment was carried out 
by addition of 10 ul of a X 100-fold concentrated cytokine into 1 ml 
of fresh culture medium. Where IGF-I pretreatment was used, IL-lp 
or combined cytokines were added to the same IGF-I-containing cul-
ture dish for a further 24-48 h. After treatment the islets were re-
moved from culture and analysed for insulin secretory responsiveness, 
nitric oxide synthase activity or expression, and apoptotic nuclear 
bodies. 
2.2. Islet insulin secretion response 
Islets were removed from culture and preincubated for 1 h in phys-
iological buffer containing 2 mM glucose [11]. The insulin secretory 
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response was measured from groups of three islets incubated in 0.6 ml 
buffer containing 20 mM glucose for 30 min at 37°C. At the end of 
the incubation a 0.3 ml aliquot was removed and assayed for secreted 
insulin. Acid ethanol (cone. HC1: water xthanol 0.45:7:23 v/v/v) (0.3 
ml) was added to the islet residue and left overnight at 4°C to extract 
insulin from P-cell granules; extracts were then radioimmunoassayed 
for insulin. Insulin was assayed using rat insulin standard, guinea pig 
insulin antiserum and 126I-labelled bovine insulin [11]. Insulin secreted 
was expressed as a percentage of islet insulin content, to take account 
of possible changes in insulin stores or islet cell number after cytokine 
treatment. 
2.3. Nitric oxide synthase assay 
The assay is based on the conversion of radiolabelled arginine to 
labelled citrulline and nitric oxide and has been described previously 
[22]. 
2.4. Detection of nitric oxide synthase by Western blotting 
Following treatments in culture, rat islets were sonicated in 100 pi 
of ice-cold Tris-HCl buffer (pH 7.6, 0.05 M) containing EDTA (0.5 
mM), EGTA (0.5 mM), leupeptin (1 uM), pepstatin A (1 uM), phe-
nylmethylsulphonyl fluoride (0.1 mM) and dithiothreitol (1 |lM) using 
an MSE 150 W ultrasonic disintegrator MK.2 at an amplitude of 15 
um for 15 s [22]. The sonicated samples were centrifuged at 
105 000 Xg for 1 h at 4°C. The supernatant was mixed 1:1 (v/v) 
with double strength sample buffer (0.125 M Tris-HCl pH 6.8, 4% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, bromophenol blue) and 
boiled for 3 min to denature the proteins. The protein content of the 
samples was determined [8] and gel lanes were equiloaded. The sam-
ples were separated on a 10% polyacrylamide separating gel at 150 V 
for 30 min. The separated proteins were blotted onto a PVDF mem-
brane (pore size 0.45 |xm) at 25 V for 105 min using a semi-dry trans-
fer system. The PVDF membrane was blocked with 5% (w/v) milk 
protein in TBS/Tween (Tris-base (10 mM), sodium chloride (100 mM) 
and 0.1% (v/v) Tween 20; pH 7.4) for 1 h at room temperature 
followed by incubation overnight at 4°C in a solution of the primary 
antibody, an anti-iNOS (murine macrophage, inducible) rabbit poly-
clonal antibody, diluted in TBS/Tween at 1:1000. Following thorough 
washing in TBS/Tween the PVDF membrane was incubated for 1 h 
with an anti-rabbit IgG secondary antibody conjugated to horseradish 
peroxidase before being visualised using an enhanced chemilumines-
cence kit according to the manufacturer's instructions. The optical 
intensity of the iNOS band was determined using a Sharp high reso-
lution colour scanner and Imagemaster software (Pharmacia Biotech), 
the band in growth factor pretreated or control islets was compared to 
that in islets treated with IL-lp and expressed as a percentage of 
iNOS expression in the IL-ip treated islets. 
2.5. Use of acridine orange to visualise apoptotic cells 
For determinations of cell death using acridine orange cytochemis-
try collagenase-isolated neonatal rat islets were treated in culture me-
dium with or without IGF-I for 24 h prior to treatment with either 
IL-ip alone or IL-ip combined with TNF-oc and IFN-y for 48 h. Islets 
were also treated with combined cytokines in arginine-free medium 
supplemented with the arginine analogue, NMMA (1 mM). Islets 
were further trypsinised to disperse into single cells which were cen-
trifuged at 500Xg for 2 min and resuspended in 20 ul of culture 
medium. 10 jxl of homogeneous cell suspension was mixed with an 
equal volume of acridine orange solution in culture medium, final 
concentration acridine orange was 10 Ug/ml, transferred to a micro-
scope slide and viewed on a Zeiss microscope using a narrow band 
fluorescence filter. Nuclei were counted and analysed immediately 
after acridine staining [16]; those showing apoptotic figures - DNA 
condensed into rounded, brightly fluorescing fragments - were re-
corded and the percent apoptosis calculated [16]. 
2.6. Statistical analysis 
The data are presented as means ± S.E.M. The significance of differ-
ences between treatments was determined by Student's unpaired (-test 
or one-way analysis of variance. 
3. Results 
Treatment of isolated rat islets of Langerhans for 24 h with 
IL-ip (100 pM) resulted in an inhibition of glucose-stimulated 
insulin secretion (Fig. 1). Treatment of islets with IGF-I (10 
nM), simultaneously with IL-ip (100 pM), failed to restore 
insulin secretion inhibited by IL-lp (Fig. 1). However, 24 h 
pretreatment of islets with 10 nM IGF-I protected against IL-
lp-mediated inhibition of insulin secretion (Fig. 1); a lower 
dose of IGF-I (In M) had no beneficial effect (control insulin 
secretion, expressed as a percent of insulin stored in same 
group of islets 3.1 ±0.2; IL-ip : 1.5±0.1; IL-ip+IGF-I 
(1 nM): 1.7 ±0.3; IGF-I (1 nM): 3.3 ±0.8; n = 4). IGF-I treat-
ment, on its own, for 24 h or 48 h had no effect on subsequent 
insulin secretion from rat islets (Fig. 1). Neither growth factor 
nor cytokine treatment had any significant effect on rat islet 
insulin content (J.G. Mabley, unpublished observations). Ni-
tric oxide synthase induction and activity were determined by 
Western blotting and enzyme activity assay. IGF-I (10 nM) 
pretreatment reduced the IL-ip-mediated rise in nitric oxide 
synthase conversion of arginine to citrulline plus nitric oxide 
(Fig. 2A) and decreased expression of inducible nitric oxide 
synthase (Fig. 2A,B). IGF-I (10 nM) treatment, alone, did not 
affect expression of nitric oxide synthase but increased argi-
nine conversion significantly, although to less than half the 
level seen with IL-ip alone (Fig. 2A,B). Treatment with IL-
lp (50 pM) for 48 h increased islet cell death (Fig. 3), the level 
of apoptosis was greatly enhanced when IL-ip was combined 
with TNF-oc (50 pM) and IFN-y (2 U/ml) (Fig. 3). Treatment 
of rat islets with combined cytokines in arginine-free medium 
supplemented with the arginine analogue NMMA (1 mM) 
prevented induction of apoptosis (Fig. 3). Pretreatment with 
IGF-I (10 nM) for 24 h prior to cytokine addition had no 
significant effect on the variable level of apoptosis induced by 
s v 
ga 
.2 o 
2.9 
o — 
<a 3 
<*> 5 5 
e.S 
£•-
4.0 
3.5 
3.0 
2.5 
2.0 
1.5 
1.0 
0.5 
0.0 
X 
1 
X 
0 Control 
■ IL-lf5(24h) 
□ IGF I cotreatment + IL-1I5 
M IGF I pretreatment + IL-IB 
□ I G F I ( 2 4 h ) 
□ I G F I ( 4 8 h ) 
Fig. 1. Pretreatment, but not simultaneous treatment, of rat islets of 
Langerhans with IGF-I (10 nM) prevents IL-ip (100 pM)-mediated 
inhibition of glucose-induced insulin secretion. IGF-I alone for 24 
or 48 h has no effect. Insulin secretion from control rat islets was 
1.1 ±0.14 ng insulin/islet/30 min (n = 4). Values are mean±S.E.M. 
of insulin secretion expressed as a percentage of islet insulin content 
from 3-6 separate isolates (6-8 observations per isolate), using Stu-
dent's Mest **P<0.01 vs. control and n P < 0 . 0 1 vs. IL-ip. 
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IL-1(3 alone but protected rat islets from apoptosis induced by 
combined cytokines (Fig. 3), IGF-I alone had no effect. 
4. Discussion 
We have demonstrated that IGF-I blocks IL- ip ' s inhibitory 
action on glucose-stimulated insulin secretion from rat islets 
of Langerhans. This protection is evident only if islets have 
been pretreated - rather than co-treated - with IGF-I . In our 
experiments, exposure of rat islets for either 24 or 48 h to 
IGF-I had no effect on insulin secretion, although there are 
reported observations that 2 h treatment of either perfused 
islets or pancreas with IGF-I caused an inhibition of insulin 
secretion [3,4]. Pretreatment of rat islets in culture with con-
centrations of IGF- I lower than 10 n M did not oppose IL-
l(3's inhibitory effects in current experiments, where foetal calf 
serum concentrations of 5% were used throughout . We have 
examined the efficacy of IGF-I pretreatments in culture media 
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Fig. 2. Pretreatment of islets with IGF-I attenuated the IL-ip in-
creased activity and expression of inducible nitric oxide synthase. 
Groups of islets were pretreated with IGF-I (10 nM) for 24 h prior 
to addition of IL-1(3 (100 pM) for a further 24 h. Nitric oxide syn-
thase enzyme activity in islet cytosol (A) was determined in a 45 
min in vitro assay; values are mean ± S.E.M. nmole arginine con-
verted/mg islet protein for 3-4 islet isolates (2 observations per iso-
late). Statistical significance were determined using one-way analysis 
of variance; *P<0.05 vs. control, 1"P<0.05 vs. control and IL-lp. 
The intensity of nitric oxide synthase protein bands visualised by 
ECL development of Western blots from treated islets was deter-
mined and expressed as a percentage that observed with IL-1(3 treat-
ment (A), values are mean ± S.E.M. n = 4 separate experiments 
A P<0 .05 vs. control and +P<0.05 vs. IL-lp by Student's f-test 
(A). Pretreatment of islets with IGFI prevented expression of IL-
lP-induced iNOS shown by Western blotting (B); a protein extract 
of macrophage iNOS supplied by Affiniti with the iNOS polyclonal 
antibody is shown for comparison. 
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Fig. 3. Treatment of neonatal rat islets with IL-lp (50 pM) alone or 
combined with TNF-cc (50 pM) and IFN-y (2 U/ml) for 48 h in-
creased apoptosis observed using acridine orange cytochemistry. An 
arginine analogue, NMMA (1 mM), prevented cytokine-mediated is-
let cell death. Pretreatment with IGF-I (10 nM) for 24 h also signifi-
cantly protected rat islets from induction of apoptosis by combined 
cytokines. The number of nuclei observed is written above each 
treatment column. Values are mean ± S.E.M. of percent of nuclei 
showing apoptotic bodies (4-7 experiments), using Student's Mest 
**P<0.01 vs. control; t t P < 0 . 0 1 vs. combined cytokine treatment. 
containing 1% and 0 .1% serum, and found that concentra-
tions of 1 n M or 0.1 n M IGF-I significantly reversed I L - i p 
inhibition of insulin secretion under these conditions [23]. It is 
not known whether IGF- I binding proteins in foetal calf se-
rum are responsible for serum dependence of protective ef-
fects, al though binding proteins are known to regulate the 
plasma level, half life and biological activity of IGF- I [1,24]. 
IL- lp ' s inhibition of rat islet insulin secretion in the short 
term is mediated, to a significant extent, by induction of nitric 
oxide synthase and the formation of nitric oxide [9]. Pretreat-
ment of rat islets with IGF- I inhibited the IL-ip-mediated 
increase in cytosolic conversion of arginine to citrulline and 
nitric oxide shown here. Other growth factors lower the ac-
tivity of inducible nitric oxide synthase by decreasing the 
availability of the substrate arginine, through upregulation 
of arginase activity [25], or restricting essential co-factors 
such as tetrahydrobiopterin [26]. A role for arginase has 
been proposed in cytokine and prostaglandin suppression of 
nitric oxide synthase activity [27]. The low level of arginine 
conversion in untreated islets is decreased further by valine, 
an inhibitor of arginase (J.G. Mabley, unpublished observa-
tions), and IGF-I alone increased islet arginine conversion, 
which could indicate an increase in arginase activity [22]. 
However, it is unlikely that IGF-I lowers nitric oxide synthase 
activity via modulat ion of arginase since it inhibited the ex-
pression of nitric oxide synthase, as determined by Western 
blotting. The elevation of cytosolic arginine conversion in 
IGF-I-treated islets, compared to control islets, may also be 
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attributable to IGF-I's ability to stimulate constitutive nitric 
oxide synthase [28] which is found, not only in the insulin-
containing cells of the islet [8], but also in endothelial cells 
lining the capillary blood vessels of islets [29]. 
A number of cytokines which prevent induction of nitric 
oxide synthase in other cell types have proved ineffective in 
protecting rat islets from IL-l(3's effects. Interleukin-4 [30], 
interleukin-10 [31] and interleukin-13 [32] were shown to be 
unable to reverse either IL-ip-mediated inhibition of insulin 
secretion or stimulation of nitric oxide formation in rat islets. 
However, transforming growth factor pi (TGFpl), another 
well-known inhibitor of nitric oxide synthase induction [33], 
inhibits cytokine-mediated induction of nitric oxide synthase 
in the insulin-containing cell line, RINm5F, and protects 
against inhibition of insulin secretion, decreased protein syn-
thesis and loss of cell viability [34]. TGFpi pretreatment of rat 
islets of Langerhans also prevents IL-lp's inhibition of insulin 
secretion, but its effects on nitric oxide synthase induction in 
islets are equivocal [35]. 
Induction of apoptosis in rat islet cells by combined cyto-
kine treatment is prevented by an arginine analogue. This 
confirms our previous findings that nitric oxide generated 
chemically induces loss of islet cell viability and apoptosis 
[16], and suggests that cytokine-mediated generation of nitric 
oxide may signal islet cell death. IGF-I can activate phospha-
tidylinositol-3-kinase which in turn activates the serine-threo-
nine kinase protein kinase B/Akt [36], which has been shown 
to prevent apoptosis [36] and regulate neuronal survival [37]; 
mechanisms other than inhibition of nitric oxide formation 
may mediate IGF-I's anti-apoptotic effect in rat islets of Lan-
gerhans. An interesting link between activation of phosphati-
dylinositol 3-kinase and inhibition of iNOS transcription by 
interleukin-13 was recently observed in an epithelial cell line 
[38]. 
In conclusion, IGF-I may antagonise the inhibitory effect of 
IL-lp on insulin secretion or cytokine-mediated apoptosis by 
lowering induction of nitric oxide synthase and nitric oxide 
formation. 
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